{"disease":{"id":"wild-type-transthyretin-amyloidosis","name":"wild type transthyretin amyloidosis"},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04276220","title":"Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT03966105","title":"Prevalence of Wild Type ATTR","phase":"","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Oncology Institute of Southern Switzerland","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT05023889","title":"Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}